المؤلفون: F. A. Abbasov, G. V. Zemtsova, P. A. Popov, K. I. Chekhonatskaya, D. V. Kukhno, M. M. Severova, M. V. Shmyreva, A. A. Kindarova, D. Yu. Schekochikhin, Ф. А. Аббасов, Г. В. Земцова, П. А. Попов, К. И. Чехонацкая, Д. В. Кухно, М. М. Северова, М. В. Шмырева, А. А. Киндарова, Д. Ю. Щекочихин

المصدر: Neuromuscular Diseases; Том 13, № 2 (2023); 72-82 ; Нервно-мышечные болезни; Том 13, № 2 (2023); 72-82 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2023-13-2

مصطلحات موضوعية: креатинфосфокиназа, polymyositis, anti‑SRP, inflammatory myopathies, creatine phosphokinase, полимиозит, анти‑SRP, воспалительные миопатии

وصف الملف: application/pdf

Relation: https://nmb.abvpress.ru/jour/article/view/545/352; Malik A., Hayat G., Kalia J.S. et al. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol 2016;7:64. DOI:10.3389/fneur.2016.00064; Pinal-Fernandez I., Casal-Dominguez M., Mammen A.L. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 2018;20(4):21. DOI:10.1007/s11926-018-0732-6; McGrath E.R., Doughty C.T., Amato A.A. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics 2018;15(4):976–94. DOI:10.1007/s13311-018-00676-2; Ghirardello A., Borella E., Beggio M. et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014;5(3):69–75. DOI:10.1007/s13317-014-0060-4; Betteridge Z., McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280(1):8–23. DOI:10.1111/joim.12451; Антелава О.А. Полимиозит/дерматомиозит: дифференциаль ная диагностика. Научно-практическая ревматология 2016;54(2):191–8. DOI:10.14412/1995-4484-2016-191-198; Rodríguez-Muguruza S., Lozano-Ramos I., Coll-Canti J. et al. Anti-SRP auto-antibodies are not specific for myositis: report of 8 cases. Joint Bone Spine 2017;84(1):103–5. DOI:10.1016/j.jbspin.2015.12.005; Satoh M., Tanaka S., Ceribelli A. et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52(1):1–19. DOI:10.1007/s12016-015-8510-y; Wang L., Liu L., Hao H. et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014;24(4):335–41. DOI:10.1016/j.nmd.2014.01.002; Suzuki S., Nishikawa A., Kuwana M. et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61. DOI:10.1186/s13023-015-0277-y; Allenbach Y., Mammen A.L., Benveniste O. et al. Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 2018;28(1):87–99. DOI:10.1016/j.nmd.2017.09.016; Pinal-Fernandez I., Casal-Dominguez M., Carrino J.A. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017;76(4):681–87. DOI:10.1136/annrheumdis-2016-210198; Lundberg I.E., Tjärnlund A., Bottai M. et al. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–64. DOI:10.1136/annrheumdis-2017-211468; Dimachkie M.M., Barohn R.J., Amato A. Idiopathic inflammatory myopathies. Neurol Clin 2014;32:595–628. DOI:10.1016/j.ncl.2014.04.007; Mammen A. Autoimmune muscle disease. Handbook of clinical neurology. 2016;133:467–84. DOI: 1016/B978-0-444-63432-0.00025-6; Kassardjian C.D, Lennon V.A., Alfugham N.B. et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015;72:996–1003. DOI:10.1001/jamaneurol.2015.1207; Kim H.I., Chung S.H., Hwang J.E. et al. Dermatomyositis associated with cancer of unknown primary site. J Korean Med Sci 2007;22 Suppl(Suppl):S174–7. DOI:10.3346/jkms.2007.22.S.S174; Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21(10):1855–9.; Hill C.L., Zhang Y., Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357(9250):96–100. DOI:10.1016/S0140-6736(00)03540-6; Allenbach Y., Keraen J., Bouvier A.M. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016;139(Pt 8):2131–5. DOI:10.1093/brain/aww054; Pinal-Fernandez I., Parks C., Werner J.L. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2017;69(2):263–70. DOI:10.1002/acr.22920; Watanabe Y., Uruha A., Suzuki S. et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosur Psychiatry 2016;87:1038–44. DOI:10.1136/jnnp-2016-313166; https://nmb.abvpress.ru/jour/article/view/545

الاتاحة: https://nmb.abvpress.ru/jour/article/view/545
https://doi.org/10.17650/2222-8721-2023-13-2-72-82

المؤلفون: E. V. Yakovenko, F. A. Abbasov, Е. В. Яковенко, Ф. А. Аббасов

المساهمون: This article has been supported by Servier., Статья спонсируется компанией «Сервье».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 4 (2022); 103-107 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 4 (2022); 103-107 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-4

مصطلحات موضوعية: пирибедил, non-motor symptoms, apathy, depression, dementia, piribedil, немоторные симптомы, апатия, депрессия, деменция

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1869/1446; Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson's disease. J Neurol. 2008 Sep;255 Suppl 5:18-32. doi:10.1007/s00415-008-5004-3; Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi:10.1002/mds.26424; Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014 Oct;14(5):310-22. doi:10.1136/practneurol-2013-000741. Epub 2014 Apr 3.; Fox SH, Katzenschlager R, Lim SY, et al. Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66. doi:10.1002/mds.27372. Epub 2018 Mar 23.; Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease – an evidencebased medicine review. Mov Disord. 2019 Feb;34(2):180-98. doi:10.1002/mds.27602. Epub 2019 Jan 17.; Титова НВ, Чаудхури КР. Немоторные симптомы болезни Паркинсона: подводная часть айсберга. Анналы клинической и экспериментальной неврологии. 2017;11(4):5-18. doi:10.18454/ACEN.2017.4.1; Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002 Apr;249(4):419-23. doi:10.1007/s004150200032; Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015 May;14(5):518-31. doi:10.1016/S1474-4422(15)00019-8. Epub 2015 Apr 12.; Santangelo G, Trojano L, Barone P, et al. Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol. 2013 Jan 1;27(4):501-13. doi:10.3233/BEN-129025; Santangelo G, D’Iorio A, Maggi G, et al. Cognitive correlates of “pure apathy” in Parkinson's disease. Parkinsonism Relat Disord. 2018 Aug;53:101-4. doi:10.1016/j.parkreldis.2018.04.023. Epub 2018 Apr 24.; Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form. Clin Neuropharmacol. 1989 Feb;12(1):23-8.; Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. 2006 Apr;21(4):500-9. doi:10.1002/mds.20750; Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239 Suppl 1:S28-34. doi:10.1007/BF00819564; Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016 Aug;31(8):1125-33. doi:10.1002/mds.26643. Epub 2016 Apr 29.; Zhu K, van Hilten JJ, Marinus J. Onset and evolution of anxiety in Parkinson's disease. Eur J Neurol. 2017 Feb;24(2):404-11. doi:10.1111/ene.13217. Epub 2016 Dec 29.; Pertovaara A, Haapalinna A, Sirvio J, et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005 Autumn;11(3):273-88. doi:10.1111/j.1527-3458.2005.tb00047.x; Tellez S, Colpaert F, Marien M. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. J Neurochem. 1997 Feb;68(2):778-85. doi:10.1046/j.1471-4159.1997.68020778.x; Scheinin M, Sallinen J, Haapalinna A. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 2001 Apr 6;68(19-20):2277-85. doi:10.1016/s0024-3205(01)01016-5; Rizk P, Salazar J, Raisman-Vozari R, et al. The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology. 2006 Jun;31(6):1146-57. doi:10.1038/sj.npp.1300954; Smith L, De Salvia M, Jenner P, et al. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord. 1996 Mar;11(2):125-35. doi:10.1002/mds.870110203; Smith LA, Jackson MG, Bonhomme C, et al. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol. 2000 May-Jun;23(3):133-42. doi:10.1097/00002826-200005000-00002; Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901. doi:10.1002/mds.10200; Millan MJ, Cussac D, Milligan G, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther. 2001 Jun;297(3):876-87.; Turle-Lorenzo N, Maurin B, Puma C, et al. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson’s disease. J Pharmacol Exp Ther. 2006 Nov;319(2):914-23. doi:10.1124/jpet.106.109207. Epub 2006 Aug 18.; Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer’s disease and the normal. J Neurochem. 1986;47:1948-54.; Marighetto A, Valerio S, Philippin JN, et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J Psychopharmacol. 2008 Jul;22(5):511-21. doi:10.1177/0269881107083836. Epub 2008 Feb 28.; Brocco M, Dekeyne A, Papp M, et al. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol. 2006 Nov;17(7):559-72. doi:10.1097/01.fbp.0000236267.41806.5b; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013 May;136(Pt 5):1568-77. doi:10.1093/brain/awt067. Epub 2013 Mar 29.; Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014 JulAug;37(4):116-22. doi:10.1097/WNF.0000000000000041; Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology. 2004 Nov;176(2):175-81. doi:10.1007/s00213-004-1869-8. Epub 2004 May 12.; Schuck S, Bentue-Ferrer D, Kleinermans D, et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol. 2002 Feb;16(1):57-65. doi:10.1046/j.1472-8206.2002.00070.x; Straka I, Minar M, Skorvanek M, et al. Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. Front Neurol. 2019 Jul 31;10:799. doi:10.3389/fneur.2019.00799. eCollection 2019.; Daley DJ, Myint PK, Gray RJ, Deane KH. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord. 2012 Dec;18(10):1053-61. doi:10.1016/j.parkreldis.2012.09.004. Epub 2012 Sep 28.; https://nnp.ima-press.net/nnp/article/view/1869

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1869
https://doi.org/10.14412/2074-2711-2022-4-103-107